Several studies have shown that RIG-I pathway induction influences the initiation of T cell responses upon viral infection [33,34] and that the efficacy of experimental IAV vaccines can be boosted by co-administration of RIG-I agonists [35–37]. The gene discussed is RIGI; the disease is viral infectious disease.